Healthcare


 Is the Biotech Sector on the Verge of a Major Breakthrough?

Is the Biotech Sector on the Verge of a Major Breakthrough?

February 01, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Emyria's MDMA Trial Shows Lasting PTSD Relief,: Emyria (ASX:EMD) reports its MDMA-based therapy continues demonstrating notable improvements in PTSD symptoms, even months after treatment.,Argenica's Breakthrough in Traumatic Brain Injury...

 Is This Quiet Stock About to Shake Up the Market?

Is This Quiet Stock About to Shake Up the Market?

January 31, 2025 03:31 PM AEDT| By Team Kalkine Media

Highlights:,Alterity Therapeutics' stock surged by 260% in the past year.,Recent capital raise strengthens the company's financial position.,Investors should stay informed about possible risks linked to its outlook.,Alterity Therapeutics (ASX:ATH), a...

 Prescient Therapeutics Gears Up for Transformative Year with New Leadership and Key FDA Clearance

Prescient Therapeutics Gears Up for Transformative Year with New Leadership and Key FDA Clearance

January 31, 2025 01:38 PM AEDT| By Team Kalkine Media

Highlights:,New CEO James McDonnell,appointed,and FDA clearance received for PTX-100 Phase 2 clinical trial.,Successful IND application for PTX-100 Phase 2 trial in r/,rCTCL,, with immediate initiation.,Significant progress,in,CellPryme,and,OmniCAR,d...

 Race Oncology (ASX:RAC) Advances RC220 Phase 1 Trial and Strengthens Leadership Team

Race Oncology (ASX:RAC) Advances RC220 Phase 1 Trial and Strengthens Leadership Team

January 31, 2025 12:12 PM AEDT| By Team Kalkine Media

Highlights,RC220 Phase 1 Trial Progress,:,Ethics and regulatory submissions completed, with first patient treatment,anticipated,in Q1 CY2025.,Leadership Expansion,:,Appointment of Dr Megan Baldwin as an independent non-executive director, along with...

 Mesoblast (ASX:MSB) Advances Ryoncil Launch Following FDA Approval

Mesoblast (ASX:MSB) Advances Ryoncil Launch Following FDA Approval

January 31, 2025 11:12 AM AEDT| By Team Kalkine Media

Highlights:,Mesoblast (,ASX:MSB,) secures $260 million funding,for the commercial launch of,Ryoncil,in the US.,Ryoncil,gains FDA approval,, leading to a 54% surge in Mesoblast shares on December 19.,Ryoncil,targets,pediatric,complications,arising fro...

 ResMed Shares Surge on Q2 Earnings Report, Revenue Jumps 10%

ResMed Shares Surge on Q2 Earnings Report, Revenue Jumps 10%

January 31, 2025 11:11 AM AEDT| By Team Kalkine Media

Highlights,Revenue Growth:,ResMed posted a 10% year-over-year revenue increase to,$1.3 billion,, exceeding market expectations.,Profit Surge:,Operating income jumped,52%,to,$417.2 million,, while non-GAAP net income rose,29%,to,$358.3 million,.,Posit...

 How Are Paradigm Biopharmaceuticals' Strategic Initiatives Shaping Its Future?

How Are Paradigm Biopharmaceuticals' Strategic Initiatives Shaping Its Future?

January 31, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Paradigm Biopharmaceuticals introduces a loyalty and piggyback options offer, aimed at raising over $110 million.,Shareholders can benefit from additional shares through the company's loyalty options program.,The company prepares to launc...

 What’s Driving the Surge in ASX Health Stocks?

What’s Driving the Surge in ASX Health Stocks?

January 31, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,The S&P/ASX 200 Health Care Index rose by 3.3% last week, outperforming the general market's 1.9% increase.,Microba’s quarterly sales surged, while Mach7 Technologies initiated a $5 million share buyback.,Aroa Biosurgery faced a setback fo...

 Steady Growth at Medical Developments International Limited (ASX:MVP) Supports Its Share Price

Steady Growth at Medical Developments International Limited (ASX:MVP) Supports Its Share Price

January 31, 2025 09:31 AM AEDT| By Team Kalkine Media

Understanding Medical Developments International's Current Valuation

 Explore ASX Penny Stocks Highlighting Mayne Pharma Group and Two More

Explore ASX Penny Stocks Highlighting Mayne Pharma Group and Two More

January 30, 2025 11:30 PM AEDT| By Team Kalkine Media

Exploring ASX Penny Stocks Amid Market Dynamics

 EZZ Life Science (ASX:EZZ) Lags, But Strong Financials Signal Potential

EZZ Life Science (ASX:EZZ) Lags, But Strong Financials Signal Potential

January 30, 2025 01:32 PM AEDT| By Team Kalkine Media

EZZ Life Science Holdings Limited (ASX:EZZ) Stock Has Been Underperforming Recently, Yet Financials Show Strength: Is It a Good Opportunity for Potential Shareholders?

 AdAlta strengthens leadership in the second quarter of fiscal year 2025 to enhance growth strategy.

AdAlta strengthens leadership in the second quarter of fiscal year 2025 to enhance growth strategy.

January 30, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,AdAlta expands leadership team with new board members and advisors to enhance growth plans.,First non-binding term sheet signed for East to West cellular therapy strategy in China.,Ongoing momentum in cellular immunotherapy and fibrosis tr...

 Why Is This Low-Key Stock Suddenly Making Waves?

Why Is This Low-Key Stock Suddenly Making Waves?

January 30, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Blinklab Initiates FDA Study:,Blinklab (ASX:BB1) has launched an FDA registrational study for its Dx 1 platform, aimed at improving autism diagnosis, with final results expected by the end of CY25.,Mach7 Technologies Reports Growth:,Mach7...

 ASX Quarterly Health Update: Bioxyne Sees 77% Revenue Increase, Radiopharm Debuts on Nasdaq

ASX Quarterly Health Update: Bioxyne Sees 77% Revenue Increase, Radiopharm Debuts on Nasdaq

January 30, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Bioxyne (ASX:BXN) achieves significant revenue growth with expanded product offerings.,Radiopharm Theranostics (ASX:RAD) makes progress with cancer therapies and strengthens US presence.,Tryptamine Therapeutics (ASX:TYP) advances in clini...

 Bio-Gene Secures U.S. Defence Contracts for Innovative Insecticides, Shares Up 130%

Bio-Gene Secures U.S. Defence Contracts for Innovative Insecticides, Shares Up 130%

January 29, 2025 01:33 PM AEDT| By Team Kalkine Media

Highlights,Major U.S. Defence Grants:,Bio-Gene Technology receives $3 million in contracts to develop its flagship insecticides.,Wearable Insecticide:,A $1.6 million grant will fund the development of Flavocide as a wearable product.,Bed Bug Solution...

 Is Mesoblast Revolutionizing Stem-Cell Therapy for Inflammatory Diseases?

Is Mesoblast Revolutionizing Stem-Cell Therapy for Inflammatory Diseases?

January 29, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Mesoblast's Ryoncil therapy gains FDA approval for treating children with steroid-resistant Graft-versus-Host Disease (GvHD).,The company secured significant funding to expand its therapies for chronic heart disease and back pain.,Mesobla...

 When Might Cyclopharm Limited (ASX:CYC) Become Profitable?

When Might Cyclopharm Limited (ASX:CYC) Become Profitable?

January 28, 2025 07:30 PM AEDT| By Team Kalkine Media

Highlights,Cyclopharm Limited is nearing breakeven,Average annual growth rate of 105% expected,No debt on balance sheet,Cyclopharm Limited (,ASX: CYC,), a prominent player in the medical equipment and radiopharmaceutical market across the Asia Pacifi...

 Sigma Healthcare Shares Surge 10% Amid Strong Merger Partner Performance

Sigma Healthcare Shares Surge 10% Amid Strong Merger Partner Performance

January 28, 2025 02:16 PM AEDT| By Team Kalkine Media

Highlights,Sigma Healthcare shares rise 10.2% to AU$2.975, marking their highest level since January 14, as merger news boosts investor confidence.,Chemist Warehouse, SIG's merger partner, reports 13% growth in retail sales, with record 10.3% like-fo...

 Arovella Therapeutics (ASX:ALA) Surges with 71% CAGR in Three Years, Rising 11% This Week

Arovella Therapeutics (ASX:ALA) Surges with 71% CAGR in Three Years, Rising 11% This Week

January 28, 2025 01:31 PM AEDT| By Team Kalkine Media

Arovella Therapeutics (ASX:ALA) has provided its shareholders with an impressive compound annual growth rate (CAGR) of 71% over the past three years, with an 11% increase in the last week alone.

 Radiopharmaceutical Expansion Sparks Telix Pharmaceuticals (ASX:TLX) Momentum

Radiopharmaceutical Expansion Sparks Telix Pharmaceuticals (ASX:TLX) Momentum

January 28, 2025 12:52 PM AEDT| By Team Kalkine Media

Highlights:,Acquisition of RLS,Radiopharmacies,bolsters commercial infrastructure and distribution in the US,Telix,Pharmaceuticals (,ASX:TLX,) records over +150% year-on-year returns amid broader biotech rally,Radiopharmaceutical advancements support...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.